NCT06662877 2024-10-29Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line TreatmentSun Yat-sen UniversityPhase 2/3 Not yet recruiting206 enrolled